FDA Approval: RUXIENCE (RITUXIMAB-PVVR) — Type 5 - New Formulation or New Manufacturer
Oncology
Government source· FDAverify ↗HCPCS Level II code
Q5115 — Injection, rituximab-abbs, biosimilar, (truxima), 10 mg
HCPCS Level IIVerified Oct 19, 2026
Medicare payment
—
No national Medicare fee schedule we hold prices Q5115 — the Physician Fee Schedule lists it with status indicator E (2026 file). CMS fee schedules ↗
Code definition
Code
Q5115
Code system
HCPCS Level II
Full description
Injection, rituximab-abbs, biosimilar, (truxima), 10 mg
Policy activity for HCPCS Q5115
CLV Intelligence is tracking 4 policy changes that cite HCPCS Q5115 between 2026-06-05 and 2026-10-02, drawn from 2 LCD/NCD coverage updates, 1 FDA notice and 1 proposed LCD. The changes span Oncology. 2 are flagged critical or high priority.
- LCD/NCD coverage updates
- 2
- FDA notice
- 1
- proposed LCD
- 1
Counts reflect the source documents CLV has matched to HCPCS Q5115 to date; each links to the government publication that is authoritative. Monitored daily from CMS, the Federal Register, and Medicare Administrative Contractor publications.
Recent policy changes matched to Q5115
Matched to this code by CLV analysis of each policy. The linked source document is authoritative.
Audit documentation
Building an audit file that includes HCPCS Q5115?
The Tripwire Audit Pack exports 12 months of single-specialty policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
See audit packs — $349One-time purchase · not a subscription
Get alerts when policy changes affect Q5115
Free weekly digest — no subscription required.
Get the free 90-day policy snapshot for your specialty
Free — no account required
See what CLV monitors for your specialty
Get a free 90-day sample snapshot — a PDF of every CMS and MAC policy change we tracked for your specialty and jurisdiction in the last quarter. Delivered instantly.
90-day windowPDF sample reportInstant download
By downloading, you agree to receive related policy update emails. You can unsubscribe at any time. Privacy policy